

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): December 21, 2021**

---

**TFF PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Its Charter)

---

---

**Delaware**

(State or Other Jurisdiction of  
Incorporation)

---

**001-39102**

(Commission File Number)

---

**82-4344737**

(I.R.S. Employer  
Identification Number)

**3801 S. Capital of Texas Hwy, Suite 330  
Austin, Texas 79704**

(Address of principal executive offices)

**(737) 802-1973**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Securities registered pursuant to Section 12(b) of the Act:**

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common stock: Par value \$.001	TFFP	Nasdaq Global Market

## **Item 7.01 Regulation FD Disclosure.**

On December 21, 2021, TFF Pharmaceuticals, Inc. (the “Company”) published an investor presentation on its website at <https://ir.tffpharma.com/>. A copy of the investor presentation is attached as Exhibit 99.1 hereto.

The information in this Current Report on Form 8-K, including the exhibit attached hereto, is furnished pursuant to Item 7.01 and shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K, including the exhibit attached hereto, shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act regardless of any general incorporation language in such filing.

## **Item 9.01 Financial Statements and Exhibits.**

### **(d) Exhibits**

The following exhibit is furnished with this report:

Exhibit 99.1	<a href="#">The Company's investor presentation materials</a>	Filed Electronically herewith
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)	

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**TFF PHARMACEUTICALS, INC.**

Dated: December 21, 2021

/s/ Kirk Coleman

Kirk Coleman,  
Chief Financial Officer